Added to YB: 2026-03-03
Pitch date: 2026-02-27
NOVO-B.CO [neutral]
Novo Nordisk A/S
+15.45%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 222.78
Price Target
N/A
Dividend
4.65%
EV/EBITDA
7.88
P/E
10.94
EV/Sales
3.95
Sector
Pharmaceuticals
Category
value
Show full summary:
Theodosian Capital | Stocks Update 27/2/2026 - NOVOB – Oh No(vo)
NOVO-B.CO (update): Phase III data shows CagriSema inferior to Lilly's Zepbound (20.2% vs 23.6% weight loss), challenging marketing. Stock fell below 2021 pre-Wegovy levels. Trades 11.4x fwd P/E—bad news potentially priced in, but obesity franchise headwinds mounting vs LLY competition.
Read full article (1 min)